Keywords
Peritoneal dialysis
Renal anemia
Short-term efficacy
Submitted : 2024-02-19
Accepted : 2024-03-05
Published : 2024-03-20
Abstract
Objective: To analyze the short-term curative effect of roxadustat in the treatment of renal anemia in patients with peritoneal dialysis. Methods: 70 patients with peritoneal dialysis renal anemia admitted to the dialysis department of our hospital from March 2021–March 2023 were selected as research objects, divided into a research group and a reference group according to random number drawing method, with each group consisting of 35 cases. The patients in the research group were treated with roxadustat, and those in the reference group were treated with recombinant human erythropoietin. The total efficacy, anemia index, iron metabolism index, and occurrence of adverse reactions were compared between the two groups. Results: The total efficacy of the treatment received in the research group was significantly higher than that in the reference group (P < 0.05). In terms of anemia indicators, there was no statistically significant difference between the hemoglobin (Hb), the red blood cell (RBC), and the hematocrit (HCT) of both groups (P > 0.05) before treatment. After treatment, the anemia indicators of the patients in the research group were significantly better than those in the reference group, (P < 0.05). In terms of iron metabolism, before treatment, there was no significant difference between the total iron-binding capacity (TIBC), the transferrin (TRF), the ferritin (FER), and iron (Fe) of both groups (P > 0.05). After treatment, the research group’s iron metabolism indicators were significantly better than those of the reference group (P < 0.05). The incidence of adverse reactions in the research group was significantly lower than that in the reference group (P < 0.05). Conclusion: The short-term curative effect of roxadustat in the treatment of peritoneal dialysis patients was demonstrated through this study, making it a viable treatment option.
References
Hong Y, Wang Z, Peng H, et al., 2023, Roxadustat Versus Erythropoietin in the Treatment of Elderly Hemodialysis Complicated with Renal Anemia and its Effect on Cardiovascular Indicators. Chinese Journal of Gerontology, 43(12): 2903–2906.
Huang H, Wei F, 2023, Comparison of Oral Roxadustat and Recombinant Human Erythropoietin in the Treatment of Chronic Maintenance Dialysis Patients with Renal Anemia. Chinese Contemporary Medicine, 30(16): 100–103.
Wang L, Yang M, Hou J, et al., 2023, Evaluating the Efficacy and Safety of Roxadustat in Hemodialysis Patients with Renal Anemia Based on the Changes of Erythropoietin, Interleukin-6 Levels and The Maximum Difference of Hemoglobin Before and After Treatment. Journal of Clinical Nephrology, 23(05): 357–362.
Huang S, Hu Y, 2023, Comparison of the Curative Effect of Roxadustat and Recombinant Human Erythropoietin Combined with Intravenous Iron in the Treatment of Renal Anemia in Maintenance Hemodialysis Patients with Iron Reaching the Standard. Chinese Journal of Clinicians, 51(05): 574–577.
Zhang Z, Fan J, 2023, Efficacy of Recombinant Human Erythropoietin Combined with Levocarnitine in the Treatment of Renal Anemia in Patients with Maintenance Hemodialysis and its Influence on Inflammatory Factors and Iron Metabolism. Hebei Medicine, 29(03): 486–491.
Che J, Jiang X, You F, et al., 2023, Effect of Roxadustat Treatment on Iron Metabolism-related Indexes in Patients with Diabetic Nephropathy Hemodialysis Complicated with Renal Anemia. Hebei Medicine, 45(05): 761–765 + 770.
Zhao P, Wang Z, Guo L, et al., 2023, Analysis of the Different Factors in the Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Maintenance Hemodialysis Complicated with Renal Anemia. Chinese Journal of Practical Internal Medicine, 43(03): 231–235 + 246.
Pan J, Xie A, Yan J, 2023, Treatment Effect of Levocarnitine + Erythropoietin in Patients with Diabetic Nephropathy Maintained on Hemodialysis and its Influence on Renal Anemia. New World of Diabetes, 26(05): 178–181.
Zhang Y, Ren T, 2023, Clinical Efficacy Analysis of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor in theTreatment of Renal Anemia in Maintenance Peritoneal Dialysis Patients. Clinical Internal Medicine Journal, 40 (01): 60–61.
Song C, Wang Q, Li X, et al., 2023, Evaluation of the Economics of Roxadustat Versus Recombinant Human Erythropoietin in the Treatment of Renal Anemia in Non-Dialysis Patients Based on Markov Model. Chinese Journal of Hospital Pharmacy, 43(04): 409–413.
Hsiao JK, Chen CL, Hsieh WY, et al., 2023, Theranostic Role of Iron Oxide Nanoparticle for Treating Renal Anemia: Evidence of Efficacy and Significance by MRI, Histology, and Biomarkers. Pharmaceutics, 15(6): 1714. https://doi.org/10.3390/pharmaceutics15061714
Liang Z, Fang L, Lin J, 2022, The Effect of JMS Ultrapure Dialysis on Improving the Micro-Inflammatory State of Hemodialysis Patients and the Effect on Improving the Dose of Erythropoietin Required for Renal Anemia. Practical Integrative Chinese and Western Medicine Clinic, 22(12): 99–102.
Li H, Chen X, Li G, et al., 2022, Observation on the Curative Effect of Levocarnitine Combined with Erythropoietin in the Treatment of Renal Anemia in Patients with Uremic Dialysis and its Influence on the Occurrence of Muscle Spasms During Dialysis. China Practical Medicine, 17(14): 102–105.
Wen C, Zhang H, Qin X, et al., 2022, Comparative Analysis of the Clinical Effect of Roxadustat and Erythropoietin in the Treatment of Patients with Maintenance Hemodialysis Complicated with Renal Anemia. Internal Medicine, 17(01): 83–85+ 98.
Ye H, 2022, Clinical Efficacy of Levocarnitine Combined with Recombinant Human Erythropoietin and Iron Sucrose in the Treatment of Uremia Undergoing Hemodialysis with Renal Anemia. Journal of Clinical Rational Drug Use, 15(03): 89–91.